Marker for inflammatory conditions

• US 6,500,630 B2
• Filed: 01/12/2001
• Issued: 12/31/2002
• Est. Priority Date: 01/12/2001
• Status: Expired due to Term

• Current Assignee: Mayo Foundation For Medical Education And Research (Mayo Clinic)
• Original Assignee: Mayo Foundation For Medical Education And Research (Mayo Clinic)
• Inventors: Schwartz, Robert S., Conover, Cheryl A., Bayes-Genis, Antonio
• Primary Examiner(s): Ceperley, Mary E.
• Assistant Examiner(s): TRAN, MY CHAU T
• Application Number:
  US09/760,376
• Publication Number:
  US 20020132278A1
• Time in Patent Office: 718 Days
• Field of Search: 435/7.1, 435/7.92, 435/7.94, 435/7.5, 436/501, 436/512, 436/545, 436/534, 436/546, 530/387.9, 530/388.25, 530/389.3
• US Class Current: 435/7.94
• CPC Class Codes: C07K 14/4715 Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
• CPC Class Codes: G01N 2800/324 Coronary artery diseases, e.g. angina pectoris, myocardial infarction
• CPC Class Codes: G01N 2800/368 Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
• CPC Class Codes: G01N 33/5091 for testing the pathological state of an organism
• CPC Class Codes: G01N 33/564 for pre-existing immune complex or autoimmune disease , i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
• CPC Class Codes: G01N 33/689 related to pregnancy or the gonads
• CPC Class Codes: G01N 33/6893 related to diseases not provided for elsewhere

Abstract

Use of pregnancy-associated plasma protein-A as a marker for inflammatory conditions, and in particular, for acute coronary syndromes is described.

Claims

1. A method for diagnosing an inflammatory condition, said method comprising:

a) measuring the level of pregnancy-associated plasma protein-A (PAPP-A) in a biological sample from a non-pregnant patient;

b) comparing said level with that of control subjects; and

c) diagnosing said inflammatory condition based on the level of PAPP-A relative to that of control subjects, wherein said patient is diagnosed as having said inflammatory condition if the level of PAPP-A is increased relative to that of control subjects.

2. The method of claim 1, wherein said inflammatory condition is acute coronary syndrome.

3. The method of claim 2, wherein said acute coronary syndrome is unstable angina, sudden cardiac death, or acute myocardial infarction.

4. The method of claim 1, wherein said inflammatory condition is rheumatoid arthritis.

5. The method of claim 1, wherein said inflammatory condition is Crohn'"'"'s disease or inflammatory bowel disease.

6. The method of claim 1, wherein said level of PAPP-A is measured using an immunoassay.

7. The method of claim 6, wherein said immunoassay is an ELISA.

8. The method of claim 7, wherein PAPP-A is captured with anti-PAPP-A polyclonal antibodies.

9. The method of claim 7, wherein PAPP-A is captured with an anti-PAPP-A monoclonal antibody.

10. The method of claim 1, wherein said biological sample is selected from the group consisting of whole blood, plasma, and serum.

11. The method of claim 1, wherein the method further comprises measuring the level of a polypeptide selected from the group consisting of high sensitivity C-reactive protein, creatine kinase MB, troponin I, troponin T, creatine kinase, creatinine, fibrinogen, interleukin-1, and interleukin-6, and wherein said diagnosing step is based on the level of said polypeptide and said level of PAPP-A relative to that of control subjects.